AQUESTIVE THERAPEUTICS

Aquestive Therapeutics Reports Positive Results from Latest Clinical Studies Evaluating Pharmacokinetic and Pharmacodynamic Performance of Anaphylm ™ (epinephrine) Sublingual Film and Provides Findings from Recent Auto-Injector Clinical Study

31 May 2023 08:00:00 By Nasdaq GlobeNewswire

Aquestive Therapeutics Reports First Quarter 2023 Financial Results and Provides Business Update

02 May 2023 16:31:30 By Nasdaq GlobeNewswire

Aquestive Therapeutics to Participate in Two Upcoming Investor Conferences

26 Apr 2023 08:00:00 By Nasdaq GlobeNewswire

Aquestive Therapeutics Receives Conditional FDA Acceptance of Proprietary Name Anaphylm™ for Lead Candidate AQST-109 (Epinephrine Sublingual Film)

20 Apr 2023 08:00:00 By Nasdaq GlobeNewswire

Aquestive Therapeutics to Report First Quarter 2023 Financial Results and Recent Business Highlights on May 2 and Host Conference Call on May 3 at 8:00 a.m. ET

18 Apr 2023 08:00:02 By Nasdaq GlobeNewswire

Aquestive Therapeutics Expands License and Supply Agreement with Pharmanovia for Libervant™ (diazepam) Buccal Film to Additional Global Markets

29 Mar 2023 08:30:00 By Nasdaq GlobeNewswire

Aquestive Therapeutics Reports Fourth Quarter & Full Year 2022 Financial Results and Provides Business Update on Key 2023 Objectives

07 Mar 2023 16:01:00 By Nasdaq GlobeNewswire

Aquestive Therapeutics to Participate in Oppenheimer 33rd Annual Healthcare Conference

01 Mar 2023 08:00:01 By Nasdaq GlobeNewswire

Aquestive Therapeutics to Report Fourth Quarter 2022 Financial Results and Recent Business Highlights on March 7 and Host Conference Call on March 8 at 8:00 a.m. ET

22 Feb 2023 08:00:56 By Nasdaq GlobeNewswire

Aquestive Therapeutics to Present Positive Data from Pharmacokinetic and Pharmacodynamic Studies for AQST-109 Epinephrine Sublingual Film at American Academy of Allergy, Asthma, and Immunology (AAAAI) Annual Meeting

21 Feb 2023 08:00:03 By Nasdaq GlobeNewswire

Aquestive Therapeutics Provides Business Update and Outlines Key 2023 Objectives

06 Jan 2023 08:00:00 By Nasdaq GlobeNewswire

Aquestive Therapeutics Announces Completion of FDA End-of-Phase 2 Meeting For AQST-109 (epinephrine sublingual film)

22 Dec 2022 08:00:00 By Nasdaq GlobeNewswire

Aquestive Therapeutics Announces Publication of Crossover Food Effect Study of Diazepam Nasal Spray in Epilepsia

29 Nov 2022 08:00:02 By Nasdaq GlobeNewswire

Aquestive Therapeutics to Participate in Two Upcoming Investor Conferences

15 Nov 2022 08:00:02 By Nasdaq GlobeNewswire

Aquestive Therapeutics to Present Positive Data from Pharmacokinetic Studies for AQST-109 (epinephrine sublingual film) at American Academy of Allergy, Asthma, and Immunology (ACAAI) Annual Scientific Meeting

09 Nov 2022 16:34:06 By Nasdaq GlobeNewswire

Aquestive Therapeutics Reports Third Quarter 2022 Financial Results and Provides Business Update

01 Nov 2022 16:01:00 By Nasdaq GlobeNewswire

Aquestive Therapeutics Licenses Sympazan® (clobazam) Oral Film to Assertio Holdings, Inc.

27 Oct 2022 09:05:24 By Nasdaq GlobeNewswire

Aquestive Therapeutics Announces Positive Decision in States’ Suboxone Antitrust Lawsuit on All Claims

24 Oct 2022 08:00:00 By Nasdaq GlobeNewswire

Aquestive Therapeutics to Report Third Quarter 2022 Financial Results and Recent Business Highlights on November 1 and Host Conference Call on November 2 at 8:00 a.m. ET

19 Oct 2022 08:00:02 By Nasdaq GlobeNewswire

Aquestive Therapeutics Receives Positive FDA Written Response for AQST-109 Epinephrine Sublingual Film

11 Oct 2022 08:00:01 By Nasdaq GlobeNewswire